Pelargonic Acid Feed Treatment for ASFV Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions to prevent the spreading of viral particles in animal feed and drinking water, particularly for African Swine Fever Virus (ASFV), while ensuring safety for oral administration in animals.
Innovation Solution
The use of pelargonic acid (C9) is administered in animal feed and drinking water to inhibit, mitigate, or lower viral infections, with concentrations ranging from 1 to 10,000 ppm, optionally combined with other organic acids, to create a safe and effective treatment or prevention method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral drugs are used, then viral infections can be treated, but they cause severe side effects and drug resistance
Solution Approach 1:
The patent employs short-chain fatty acids (SCFAs) such as pelargonic acid as temporary, naturally occurring antiviral agents that act quickly to inhibit viral replication without accumulating in the body. These SCFAs are metabolized rapidly, preventing long-term side effects and resistance development, thus providing effective viral treatment with minimal harmful effects.
Solution Approach 2:
The patent changes the chemical parameters by using naturally occurring short-chain fatty acids with specific chain lengths (C4-C8) instead of conventional synthetic antivirals. This parameter change in molecular structure and natural origin provides antiviral activity through a different mechanism that does not induce resistance, while maintaining effectiveness against various viruses including influenza and SARS-CoV-2.
2Reliability
If conventional antiviral drugs are used, then viral infections can be treated, but the treatment costs are high
Solution Approach 1:
The patent utilizes inexpensive short-chain fatty acids that can be produced through natural fermentation processes or obtained from common dietary sources. These SCFAs are significantly cheaper than conventional antiviral drugs while providing effective treatment, making antiviral therapy accessible and reducing overall healthcare costs.
Solution Approach 2:
The patent leverages the body's own metabolic pathways to process and eliminate SCFAs, reducing the need for complex administration systems and expensive monitoring infrastructure. The natural metabolism of these fatty acids through existing enzymatic pathways simplifies treatment delivery and reduces associated costs.
3Reliability
If vaccines are developed for each new virus variant, then specific protection can be provided, but the development time and complexity increase
Solution Approach 1:
The patent demonstrates that short-chain fatty acids provide broad-spectrum antiviral activity against multiple virus types and variants including influenza, SARS-CoV-2, and other respiratory viruses. This universal mechanism of action eliminates the need for variant-specific treatments, allowing a single therapeutic approach to remain effective across evolving virus strains without requiring repeated development cycles.
Data Source
Figure 1~2
AI summary
The current invention relates to pelargonic acid (C9) or derivatives thereof for use in the treatment or prevention of viral infections in animals and the use of pelargonic acid for mitigating the presence of viral particles in a feed, feed ingredients or drinking water of said animals.